Therapeutic Areas

Survodutide produced a statistically significant improvement in metabolic dysfunction-associated steatohepatitis among 83% of those administered the drug compared to 18.2% of those given a placebo.

Biopharma company XYRA and FDA have concluded a series of Phase II meetings on managing key studies for potential atrial fibrillation therapy, budiodarone.

Phase Ia, open-label, escalating dose study to evaluate the safety and immunogenicity of therapeutic vaccine, TherVacB.

Enrollment and initial follow up has been completed for study set to test efficacy of cancer vaccine in individuals with Lynch syndrome.

Clinical-stage biotech’s lead drug candidate, PrimeC for the treatment of ALS demonstrated a clinically meaningful effect on quality of life and on complication free-survival for patients.

ARV-102 is a novel oral PROTAC protein degrader designed to cross the blood-brain barrier and target leucine-rich repeat kinase 2.

Phase II GenePHIT trial is evaluating the safety and efficacy of a single intracoronary infusion of AB-1002.

Partnership comes amid two promising Phase III trial results for non-opioid, non-addictive medication for fibromyalgia.

TAK-861, an oral orexin receptor 2 agonist, will begin a Phase III trial in patients with narcolepsy type 1 later in 2024.

Ongoing clinical development program for JNJ-2113 demonstrates promise of the novel oral therapy in treating immune-mediated inflammatory conditions.

Phase I trial results suggest the potential of Amgen's maridebart cafraglutide (MariTide) in allowing patients to take lower and less frequent doses while still maintaining significant weight loss.

Study indicated that nipocalimab demonstrated significant improvements in the symptoms of generalized myasthenia gravis and Sjögren's disease.

A pivotal Phase III clinical trial is currently evaluating treatment with rusfertide, a potential first-in-class treatment for polycythemia vera.

In the 72-week BALATON and COMINO trials, Vabysmo (faricimab-svoa) produced sustained retinal drying and improved vision in patients with retinal vein occlusion.

Monthly, higher doses of novel therapy SRP-5051 (vesleteplirsen) found to produce substantially greater increases in dystrophin and exon skipping compared to the lower weekly dose.

Tremfya achieved the co-primary endpoints of Scalp-Specific Investigator Global Assessment score of 0/1 and Psoriasis Scalp Severity Index 90 response at week 16 in the trial.

Data from prior Phase II study showed signs of pridopidine slowing disease progression in patients with amyotrophic lateral sclerosis.

A discussion of where cell and gene therapies are currently doing, what's on the horizon, personalization, and much more.

Utility Therapeutics’ pivmecillinam is an oral antibiotic for the treatment of uncomplicated urinary tract infections.

With $13 million grant, Vanderbilt University Medical Center will lead the new multisite trial.

A pair of clinical trials show the rapid and reliable efficacy of Zoryve in treating atopic dermatitis and seborrheic dermatitis.

Data from the Phase III LIBERTY-AD-HAFT trial show 40% of patients with atopic dermatitis with uncontrolled moderate-to-severe hand and/or foot involvement who were administered Dupixent achieved clear or almost clear skin on their hands and feet.

Clinical study identifies combination of 11 proteins that can predict long-term disability in patients with multiple sclerosis.

AbbVie will advance the clinical program for the investigational, dual-variable-domain IL 1α/1β antagonist lutikizumab to Phase III for the treatment of adults with moderate to severe hidradenitis suppurativa who previously failed anti-TNF therapy.

Phase III ASC4FIRST show Scemblix (asciminib) plus investigators’ choice of tyrosine kinase inhibitor produced a statistically significant response in patients newly diagnosed with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

The use of modeling and biosimulation can help predict potential outcomes and improve confidence in therapeutic candidates for Alzheimer disease.

Webinar Date/Time: Tuesday, February 6th, 2024 at 11am EST | 8am PST | 4pm GMT | 5pm CET

In an interview with ACT editor, Andy Studna, Hesterlee, Chief Research Officer at the Muscular Dystrophy Association discusses a new therapy for Duchenne Muscular Dystrophy, Vamorolone, and what sets it apart from other therapies in the market.

A planned analysis of the KEYNOTE-942/mRNA-4157-P201 clinical trial found that at a median follow-up of approximately three years, adjuvant treatment with Moderna’s mRNA-4157 (V940) in combination with Keytruda continued to show a clinically meaningful improvement in recurrence-free survival in patients with resected high-risk melanoma.

PrEPVacc halts study of experimental HIV vaccine regimens and a new form of oral pre-exposure prophylaxis.